CompletedNCT00095511
Aripiprazole for acute manic symptoms in bipolarity
About this title
Read the official source — NCT00095511Medication studyAges 18+United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Tuscaloosa and 37 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJune 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 615
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT00095511
- Official title
Show the full official title
A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Aripiprazole Monotherapy in the Treatment of Acutely Manic Patients With Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tuscaloosa · Scottsdale · Cerritos
35 more locations
- Garden Grove
- La Palma
- Riverside
- San Diego
- Denver
- Middletown
- New Haven
- Bradenton
- Kissimmee
- Maitland
- Augusta
- Honolulu
- Chicago
- Hoffman Estates
- Indianapolis
- Louisville
- New Orleans
- Shreveport
- Saint Charles
- Clementon
- Cedarhurst
- Elmsford
- Holliswood
- Morganton
- Raleigh
- Cincinnati
- Cleveland
- Lyndhurst
- Oklahoma City
- Norristown
- Philadelphia
- Austin
- Bellaire
- Houston
- Arlington
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including aripiprazole.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
